OPM-116
/ Oncodesign
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 06, 2024
OPM-116, a highly potent and specific PI3Kγ inhibitor to enhance antitumor immunity
(AACR 2024)
- "Tumor-associated macrophages are an integral part of the tumor microenvironment. Mario-3 phase II study safety run-in evaluating a novel triplet combination of eganelisib, atezolizumab, and nab-paclitaxel as first-line therapy for locally advanced or metastatic TNBC. AACR, Cancer Res 2021."
IO biomarker • Oncology • Triple Negative Breast Cancer • IL4 • PD-L1 • PIK3CG
1 to 1
Of
1
Go to page
1